INSIGHTS ON PHARMACEUTICAL PACKAGING
-
Can’t Afford A Head Of Clinical And CMC? Think Again
Brian James of Rondaxe, and Joanne Beck of Aerium Therapeutics, consider the basic “org chart” needed to ensure development and manufacturing success at your CDMO.
-
How Much Do You Need To Pay Your CDMOs … And When?
Striking a balance between must-haves, and thus must-pay-fors, with the need for development speed and budgetary constraints, was a serious subject for our outsourcing professionals.
-
How Much Can You Actually Rely On Your CDMO?
At our recent Outsourced Pharma Live, “How Can CMC Keep Up With The Rush To The Clinic?”, our panel of professionals draw the line on how much you can count on your CDMO to do for you, even if you are a virtual biotech.
-
“Relentless Transparency” Needed Between CDMO And Biotech Customer
Vincent Kosewski, VP, Manufacturing & Supply Chain Management, Kala Pharmaceuticals, explains his phrase for how outsourcing communication needs to be handled.
-
Speed To Clinic, Cost To Get There, And FDA Expectations5/15/2024
GSK’s Ben Stevens provides an indepth analysis of the variables regulatory bodies and developers need to balance when considering fast track designations, and the overall rush to get to the clinic.
-
When Outsourcing, Get The Right Professionals On Your Internal Team5/15/2024
In our Outsourced Pharma Live titled “How Can CMC Keep Up With The Rush To The Clinic?”, our speakers all agree: Hire strategically internally for the best results.
-
A New Acronym – CBMC? Put “Biology” In CMC? Our Panelists Think Not.5/15/2024
Chief Editor Louis Garguilo asks our panel if CMC – chemistry, manufacturing, and controls – might be outdated, and whether biology should be added to the acronym.
-
Consultants Know: Emerging Biotechs Have Outsourcing “Disconnects”5/15/2024
Missing an analysis of all the pieces involved in development outsourcing, and a loose connection between the C-suite and reality, can slow down a biotech’s program.
PHARMACEUTICAL PACKAGING SOLUTIONS
-
No matter where you are in the process of combination product development, BD can help you reach your goals.
-
Unlock an enhanced customer experience through digital transformation by applying real-time visibility into your supply chain using cross-functional workflows and data-driven insights.
-
Explore how a CDMO with dedicated quality and analytical teams, robust processes, and specialized technologies can help support your sterile injectable product from clinical to commercial.
-
With state-of-the-art manufacturing equipment, Jubilant HollisterStier has vast capabilities for the non-sterile manufacturing of ointments, creams, gels and liquid products. Our flexible filling lines support packaging into bottles, tubes and pumps.
-
Formulation and aseptic filling solutions are crucial at every stage of development. Consider a manufacturing partner who can address every challenge on the path from pre-clinical programs to commercialization.